Psychologists in Smyrna, DE Accepting Medicare

36 Psychologists found. Showing 1 - 20

Kwame Tuffuor Psychologist - Mental Retardation & Developmental Disabilities Medicare: Not Enrolled in Medicare Practice Location: 1 Hedera Ct, Smyrna, DE 19977 Phone: 302-573-1231

Erica Parker Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 82 Monrovia Ave, Smyrna, DE 19977 Phone: 302-632-1780

Melanie Eleuterio Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 22 S Main St, Smyrna, DE 19977 Phone: 302-653-8585

Maria Eyekpimi Psychologist - Mental Retardation & Developmental Disabilities Medicare: Not Enrolled in Medicare Practice Location: 150 Climbing Vine Ave, Smyrna, DE 19977 Phone: 302-573-1231

Tina Robinson Psychologist - Mental Retardation & Developmental Disabilities Medicare: Not Enrolled in Medicare Practice Location: 67 Zelkova Rd, Smyrna, DE 19977 Phone: 302-573-1231

Seibatu Gaojia, OTR/L Psychologist - Mental Retardation & Developmental Disabilities Medicare: Medicare Enrolled Practice Location: 66 Foxtrail Rd, Smyrna, DE 19977 Phone: 302-573-1231

Roderick Bookard Psychologist - Mental Retardation & Developmental Disabilities Medicare: Not Enrolled in Medicare Practice Location: 236 E Braeburn Dr, Smyrna, DE 19977 Phone: 302-573-1231

Gladys Demby Psychologist - Mental Retardation & Developmental Disabilities Medicare: Not Enrolled in Medicare Practice Location: 66 Foxtrail Rd, Smyrna, DE 19977 Phone: 302-573-1231

Dr. Paola Andrea Munoz, PSY.D., MACJ Psychologist - Clinical Medicare: Accepting Medicare Assignments Practice Location: 1181 Paddock Rd, Jtvcc - Connections Community Support Programs, Smyrna, DE 19977 Phone: 302-653-9261

Steffani Stauffer Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 80 Monrovia Ave, Smyrna, DE 19977 Phone: 302-653-3135

Shawn Hilliard Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 82 Monrovia Ave, Smyrna, DE 19977 Phone: 302-653-8585

Delore Love Psychologist - Mental Retardation & Developmental Disabilities Medicare: Not Enrolled in Medicare Practice Location: 169 E Braeburn Dr, Smyrna, DE 19977 Phone: 302-573-1231

Kallie Lutz Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 365 N Main St, Smyrna, DE 19977 Phone: 302-653-8589

Rosa Dipiazza, MS Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 20 W Frazier St, Smyrna, DE 19977 Phone: 302-653-2758

Fatmata Bah Psychologist - Mental Retardation & Developmental Disabilities Medicare: Not Enrolled in Medicare Practice Location: 653 Magnolia Ave, Smyrna, DE 19977 Phone: 302-514-9320

Charlesetta Wahlo Psychologist - Mental Retardation & Developmental Disabilities Medicare: Not Enrolled in Medicare Practice Location: 231 Azalea Dr, Smyrna, DE 19977 Phone: 302-573-1231

Allison Jeffreys Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 80 Monrovia Ave, Smyrna, DE 19977 Phone: 302-659-4330

Althia Rennie Psychologist - Mental Retardation & Developmental Disabilities Medicare: Not Enrolled in Medicare Practice Location: 34 Dilworthtown Dr, Smyrna, DE 19977 Phone: 302-573-1231

Wendy Bookard Psychologist - Mental Retardation & Developmental Disabilities Medicare: Not Enrolled in Medicare Practice Location: 236 E Braeburn Dr, Smyrna, DE 19977 Phone: 302-573-1231

Rachel Rudinoff Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 22 S Main St, Smyrna, DE 19977 Phone: 302-653-8585

News Archive

Scientists develop way of producing 3D data to show cardiac conduction system in detail

A pioneering new study is set to help surgeons repair hearts without damaging precious tissue. A team of scientists from Liverpool John Moores University, The University of Manchester, Aarhus University and Newcastle University, have developed a way of producing 3D data to show the cardiac conduction system - the special cells that enable our hearts to beat - in unprecedented detail.

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.

In rural Kentucky, an unexpected take on the health debate

Frank Browning reports for Kaiser Health News on how the health reform debate is playing out in rural Kentucky. "From a strip-mined bluff at the edge of this famous mountain town you can see one of the most concentrated and diverse sets of medical facilities in rural America: a general hospital, a psychiatric hospital, a university-based rural health care center and clinics for primary care, cancer, urology, cardiology, addiction and ear-nose-and throat problems.

IMD, BioFocus enter marketing collaboration to offer enhanced natural product discovery

BioFocus, an integrated drug discovery service partner, and InterMed Discovery GmbH (IMD), a natural product lead-discovery company, today announced a marketing collaboration to offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries. No financial details were disclosed.

FixHepC Buyers Club exposes weakness in Australian healthcare, assists patients to import life saving medication

In one of the greatest advances in medicine in decades, Hepatitis C is now largely curable. Over 200,000 Australians suffer from Hepatitis C. However the US manufacturer, Gilead Sciences Inc is attempting to charge the PBS $84,000 for a 12 week course of medication that costs under $200 dollars to manufacture.

Read more Medical News

› Verified 9 days ago

• 1(current)
• 2